Torrent Pharma Limited Q1 FY27 Earnings Call Summary

Event Participants

Executives

3
Aman, Sanjay Gupta, Sudhir Menon

Analysts

9
Abdulkader Puranwala, Damayanti Kerai, Kunal Dhamesha, Neha Manpuria, Pankaj Tibrewal, Rahul Jeewani, Shyam Srinivasan, Tushar Manudhane, Vivek Agrawal

Financials & KPIs

Geographic & Segment Commentary

India (Base Business): Q1 revenue ₹2,157 crore, +19% vs IPM +12%, driven by IPM acceleration, new launches, and volume growth from field force expansion. Curatio grew 34% on OTC ad spends and field expansion; Torrent + JB now rank #1 in the cardiac market (largest and among fastest-growing IPM segments). Top-10 brands grew 20%+, and 28 brands now exceed ₹100 crore.

JB Pharma: Revenue ₹1,201 crore (+10% YoY) with India Rx at +13% and International (incl. CDMO) at +12%. EBITDA margin at 35.3% (+6 pp) on cost synergies tracking ahead of plan. Integration underway — brand/division transfers to Torrent may cause minor transient revenue impact over next 2–3 quarters; field force attrition down to 16% in June from ~30% pre-acquisition.

Brazil: Primary sales grew only +3% CC due to a one-time channel inventory reduction (channel requests for extended credit amid rising interest costs); underlying secondary demand is strong per IQVIA at +19% vs market +4%. Generics division (~22% of sales) aided growth; rosuvastatin and azithromycin were key launch contributors.

U.S.: Revenue $44 million, +23% CC, helped by new launches and one-time opportunities. 17 products launched over the last 30 months contribute roughly $20–25 million in sales, largely offsetting price erosion. Management expects FY27 to be profitable — a turnaround from the last five years.

Germany: Revenue EUR 29 million, -9% CC. A key third-party supplier (representing 10–15% of revenue) is out of business, and the company continues to lose tender bids to peers. Management states it is "still in the middle of the woods" and requires further cost optimization.

Company-Specific & Strategic Commentary

• Merger Integration & Synergies: Merger completed July 8, 2026 — six months ahead of the initially perceived timeline. Policies and practices largely aligned; brand/division transfers initiated in July with normalization expected by Q4 FY27. First-year cost synergy target of ₹90 crore now tracking above ₹100 crore (exact figure withheld due to territory rationalization top-line impact). Manufacturing synergies are phase 2; the three-year synergy timeline could compress to two years.

• Semaglutide Franchise: Q1 combined sales of ₹50 crore with 36% combined oral + injectable share. An unforeseen supply issue with the injectable manufacturing partner (confirmed not Dr. Reddy's) has been mitigated with an alternate supply source; all Semalix SKUs expected back by end of August. Affected SKUs represent ~20% of monthly franchise contribution; oral brands and reusable SKU unaffected.

• Field Force & Productivity: Combined field force of 9,400 (base 7,200, JB 2,200) with combined PCPM just over ₹10 lakh. Further Curatio field force expansion planned in FY27; total MR strength expected to reduce to ~9,000 in Q2 as JB divisions are restructured, with end-year around the same level.

• Capital Allocation: Management will wait 12–18 months for comfort on JB before considering next M&A. Preference remains India-first for same-size opportunities, though no major India target is on the horizon; mid-size international acquisitions are possible. Net debt/EBITDA ceiling of 3–3.5x caps deal size.

Guidance & Outlook

Risks & Constraints

Q&A Highlights

JB Pharma Margins & Synergy Target

• Question: Is the 35%+ JB margin driven by cost synergies or CDMO operating leverage, and how should it look for the full year? Is the ₹90 crore synergy target being upgraded? (Kunal Dhamesha, Macquarie)
• Answer: The margin improvement is largely cost synergies implemented sooner than expected, with only a minor operating leverage contribution; margins should improve incrementally each quarter, partly reinvested in territories (Aman). Synergy realization is definitely above ₹100 crore, but the exact number is withheld due to potential top-line impact from territory rationalization (Sudhir Menon).

JB Integration, Revenue Synergies & Timeline

• Question: What exactly causes the revenue impact during integration (especially cardiac), when does it normalize, and what revenue synergies are possible? (Neha Manpuria, Bank of America)
• Answer: Brand transfers require reps to learn new territories and prescriber bases; a robust transfer process minimizes disruption, and normalization is expected by Q4 FY27 (Aman). Revenue synergy guidance will only come from next year — cardiac and gastro are key candidates. Manufacturing synergies are phase 2, and with the merger six months ahead of plan, the three-year synergy timeline could compress to two years (Sudhir Menon).

Brazil Channel Correction & Semaglutide Filing

• Question: What was the exact Brazil inventory impact, when does growth normalize, and what is the semaglutide filing status? (Kunal Dhamesha, Macquarie)
• Answer: Without the one-time inventory correction, constant currency sales would have grown 15–18%; Q2 should return to mid-teens growth per IQVIA trends (Sanjay Gupta). ANVISA is expediting semaglutide approvals — five were granted recently — and Torrent's application should be decided in "months, not years," though no precise timeline was given (Sanjay Gupta).

Semaglutide India — Supply Disruption & Market Plateau

• Question: The semaglutide market appears to be plateauing; how do you see the trajectory, injectable share recovery, and the revised annual target? (Damayanti Kerai, HSBC; Shyam Srinivasan, Goldman Sachs)
• Answer: The plateau reflects initial trial prescriptions, side-effect drop-offs, and channel overstocking — not a structural concern; the oral franchise continues well and July market traction is improving (Aman). The ₹250 crore target is no longer possible; a revised objective will come after one quarter of observing recovery. Affected SKUs are ~20% of monthly contribution; API approval is not the gating factor for share recovery (Aman). Year-one market size estimated at ₹700–800 crore (Aman).

India Growth Decomposition

• Question: Ex-Sema organic India growth is ~16%; what is driving the acceleration — market or Torrent-specific factors — and how sustainable is it? (Rahul Jeewani, IIFL; Damayanti Kerai, HSBC)
• Answer: Growth split was 5.1% volume, 7.7% price, ~6% new products vs market at 2% / 5.8% / 3.8% (Aman). Drivers include Curatio at 34%, the payoff from 2–3 years of field force expansion, and top-10 brands growing 20%+ across 28 brands above ₹100 crore. Sustainability beyond the current year is uncertain (Aman).

Base Business Gross & EBITDA Margins

• Question: Gross margin at ~78% vs 76–76.5% previously — is it sustainable? What explains the 22% OpEx increase, and what is the EBITDA margin trajectory? (Vivek Agrawal, Citigroup)
• Answer: Gains come from annual April price increases, higher branded mix (76% vs 74% historically), and positive forex; up to 77% is definitely sustainable, beyond that depends on other factors (Sudhir Menon). OpEx is inflated by forex and seasonally higher Q1 branded spends. Base business guidance remains at least 50 bps annual margin improvement; Q1 delivered exactly that, to 33.3% (Sudhir Menon).

U.S. & Germany Strategy

• Question: U.S. revenue is flat versus FY14 levels and Germany's share has fallen from 7% to 5% — how do these businesses recover? (Pankaj Tibrewal, Ikigai Asset Management)
• Answer: The U.S. is stable and will be profitable in FY27 for the first time in five years; 17 launches over 30 months contribute $20–25 million, offsetting price erosion (Sanjay Gupta). Germany faces two issues: a key supplier (10–15% of revenue) out of business and losing tender bids to competitors; further cost optimization is needed — "we are still in the middle of the woods" (Sanjay Gupta).

Capital Allocation & M&A Vision

• Question: What is the three-year vision, and will the next big capital allocation be international rather than domestic? (Pankaj Tibrewal, Ikigai Asset Management)
• Answer: Too early to assess JB at six months; management will wait 12–18 months before considering new M&A. India remains the preference for same-size opportunities, but no major India target is visible, so mid-size international acquisitions are possible. Leverage will be capped at 3–3.5x net debt/EBITDA (Aman).

Key Takeaway

Torrent Pharma reported a strong Q1 FY27 with consolidated revenue of ₹4,921 crore (+55% YoY) and operating EBITDA of ₹1,664 crore (+61%) at a 33.8% margin, reflecting the completed JB Pharma merger. The base business grew 17% (India +19% vs IPM +12%, Curatio +34%), while JB contributed ₹1,201 crore (+10%) at a 35.3% EBITDA margin, with cost synergies tracking above ₹100 crore and rising quarterly. Strategic focus centers on JB integration — brand transfers may cause transient revenue impact over the next 2–3 quarters with normalization expected by Q4 FY27 — and on the semaglutide franchise, which posted ₹50 crore Q1 sales and 36% combined share despite an injectable supply disruption scheduled to resolve by end August. Management guides to double-digit JB India Rx growth, high single to low double-digit constant currency growth, and continued ≥50 bps annual base margin improvement. Key watchpoints remain semaglutide share recovery, Germany's supplier-driven decline, and the sustainability of the volume-led IPM acceleration.